{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0005150,73,MONDO:0005150,139,-1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0005150","source":"MONDO:0005150|age-related macular degeneration","targets":["NCT00134667|Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)|TERMINATED|PHASE4|INTERVENTIONAL","NCT00135837|Photodynamic Therapy in Occult-Only Lesions (POOL)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00327470|An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD|TERMINATED|PHASE4|INTERVENTIONAL","NCT00331435|PDT Study for Exudative AMD With PCV|COMPLETED|PHASE4|INTERVENTIONAL","NCT00354445|A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00423189|Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration|TERMINATED|PHASE4|INTERVENTIONAL","NCT00478439|Investigation of Macular Pigment Augmentation on Dark Adaptation|TERMINATED|PHASE4|INTERVENTIONAL","NCT00556348|Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration|COMPLETED|PHASE4|INTERVENTIONAL","NCT00680498|Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment|COMPLETED|PHASE4|INTERVENTIONAL","NCT00805649|Combined Therapy in Age-Related Macular Degeneration (ARMD)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01148511|Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus Treat and Extend Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01165801|Size Progression of Macular Degeneration After Cataract Surgery|COMPLETED|PHASE4|INTERVENTIONAL","NCT01319188|Ranibizumab and the Risk of Arterial Thromboembolic Events|TERMINATED|PHASE4|INTERVENTIONAL","NCT01453920|Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing|COMPLETED|PHASE4|INTERVENTIONAL","NCT01464723|Study EvAluating Genotypes While Using Lucentis 2|COMPLETED|PHASE4|INTERVENTIONAL","NCT01495221|To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD|COMPLETED|PHASE4|INTERVENTIONAL","NCT01543568|Study for Recalcitrant Age Related Macular Degeneration|COMPLETED|PHASE4|INTERVENTIONAL","NCT01573572|Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium|COMPLETED|PHASE4|INTERVENTIONAL","NCT01657669|Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01670162|On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01824225|Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration|COMPLETED|PHASE4|INTERVENTIONAL","NCT01846273|Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01943396|Treatment of AMD With Rheohemapheresis /RHF/|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02002377|Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections|TERMINATED|PHASE4|INTERVENTIONAL","NCT02130024|A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT02140411|Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.|COMPLETED|PHASE4|INTERVENTIONAL","NCT02441816|VITAL - Individualising Therapy for Neovascular AMD With Aflibercept|COMPLETED|PHASE4|INTERVENTIONAL","NCT02577107|Head to Head Study of Anti-VEGF Treatment.|COMPLETED|PHASE4|INTERVENTIONAL","NCT02681783|PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02802657|Efficacy and Safety of Treat-and-Extend Regimen Versus Pro Re Nata of Conbercept in Age-related Macular Degeneration|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02864472|Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03056079|Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03056092|Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03117634|An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy|COMPLETED|PHASE4|INTERVENTIONAL","NCT03205202|Cataract and AMD in a Trial of a Multivitamin and Cocoa Extract|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03393767|Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD|COMPLETED|PHASE4|INTERVENTIONAL","NCT03409250|SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia|COMPLETED|PHASE4|INTERVENTIONAL","NCT03552770|Single or Combined Protocols for NV-AMD|COMPLETED|PHASE4|INTERVENTIONAL","NCT04018482|Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study)|COMPLETED|PHASE4|INTERVENTIONAL","NCT04679935|Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration|COMPLETED|PHASE4|INTERVENTIONAL","NCT04761341|FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment|COMPLETED|PHASE4|INTERVENTIONAL","NCT05710471|Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E|COMPLETED|PHASE4|INTERVENTIONAL","NCT06330220|Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity|COMPLETED|PHASE4|INTERVENTIONAL","NCT06683950|Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment|RECRUITING|PHASE4|INTERVENTIONAL","NCT06708624|Ocular Safety and Usability Study for FYB201 PFS|COMPLETED|PHASE4|INTERVENTIONAL","NCT06708637|Ocular Safety and Usability Study for FYB203 PFS|COMPLETED|PHASE4|INTERVENTIONAL","NCT06970665|A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration|RECRUITING|PHASE4|INTERVENTIONAL","NCT07187804|Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT00148551|Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT00215670|Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00251459|A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00275821|Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00305630|Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00321997|A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00331864|SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|COMPLETED|PHASE3|INTERVENTIONAL","NCT00332657|Anecortave Acetate Risk Reduction Trial (AART)|TERMINATED|PHASE3|INTERVENTIONAL","NCT00333216|Anecortave Acetate Risk-Reduction Trial (AART)|TERMINATED|PHASE3|INTERVENTIONAL","NCT00345176|Age-Related Eye Disease Study 2 (AREDS2)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00390026|The Avastin vs Visudyne for Neovascular AMD Study|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT00406744|Efficacy of Retreatments With Intravitreal Bevacizumab|TERMINATED|PHASE3|INTERVENTIONAL","NCT00429962|Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV|COMPLETED|PHASE3|INTERVENTIONAL","NCT00470678|EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00557791|Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT00569569|Retaane® in Age-Related Macular Degeneration|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00572039|Improving Function in Age-Related Macular Degeneration|COMPLETED|PHASE3|INTERVENTIONAL","NCT00590694|Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00593450|Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial|COMPLETED|PHASE3|INTERVENTIONAL","NCT00710229|Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00769015|Low Vision Depression Prevention Trial for Age Related Macular Degeneration|COMPLETED|PHASE3|INTERVENTIONAL","NCT00788177|Subretinal Macugen® for Neovascular Age-Related Macular Degeneration|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00800995|Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00826371|Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients|COMPLETED|PHASE3|INTERVENTIONAL","NCT00890097|Geographic Atrophy Treatment Evaluation|TERMINATED|PHASE3|INTERVENTIONAL","NCT00891735|A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01014468|Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01170767|French Evaluation Group Avastin Versus Lucentis|COMPLETED|PHASE3|INTERVENTIONAL","NCT01255774|Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01327222|Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01402544|Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT01570608|Lucentis KAV Study|COMPLETED|PHASE3|INTERVENTIONAL","NCT01940887|A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy|TERMINATED|PHASE3|INTERVENTIONAL","NCT01940900|A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy|TERMINATED|PHASE3|INTERVENTIONAL","NCT01944839|A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy|TERMINATED|PHASE3|INTERVENTIONAL","NCT01948830|Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD|COMPLETED|PHASE3|INTERVENTIONAL","NCT02035722|Intravitreal Injections-related Anxiety|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02296567|Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT02611778|Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration|COMPLETED|PHASE3|INTERVENTIONAL","NCT02727881|Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD|UNKNOWN|PHASE3|INTERVENTIONAL","NCT03150589|A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03609307|Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT03668054|Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03710564|Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections|TERMINATED|PHASE3|INTERVENTIONAL","NCT03834753|A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03844074|A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03845582|Phase 2/3 Study of ALK-001 in Geographic Atrophy|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT03954626|Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD|COMPLETED|PHASE3|INTERVENTIONAL","NCT04005352|Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)|COMPLETED|PHASE3|INTERVENTIONAL","NCT04516278|A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders|COMPLETED|PHASE3|INTERVENTIONAL","NCT04572698|A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）|UNKNOWN|PHASE3|INTERVENTIONAL","NCT04667039|Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®|UNKNOWN|PHASE3|INTERVENTIONAL"]}]}